Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors

Plain-language summary

Published 2024 in Mol Cancer Ther, this work by Murray MA and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Mechanistic study in Mol Cancer Ther (2024) on NAD+/sirtuin/longevity biology
• Adds to the foundational literature underlying NMN supplementation rationale
• First author: Murray MA

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to benefits decisions, with secondary relevance to science. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.